Education
About Us
Working with TipRanks
Follow Us
Icon plc (ICLR)
NASDAQ:ICLR
ICLR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$133.28 - $347.72
Previous CloseN/A
Volume330.38K
Average Volume (3M)1.68M
Market Cap
$10.91B
Enterprise Value$17.19B
Total Cash (Recent Filing)$526.70M
Total Debt (Recent Filing)$3.56B
Price to Earnings (P/E)14.7
Beta1.05
Next Earnings
Jul 23, 2025EPS Estimate
3.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.19
Shares Outstanding80,756,860
10 Day Avg. Volume2,521,848
30 Day Avg. Volume1,677,540
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda11.20
Forecast
1Y Price Target
$193.07Price Target Upside39.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Market PositioningICLR is well-positioned for a fast snapback in growth once market conditions improve, despite current challenges.
Share RepurchaseManagement will be active in utilizing the $750M remaining in its share repurchase authorization.
Strategic AlliancesStrategic alliances are gaining traction, both recent ones have mentioned awarded work, putting one ahead of schedule.
Bears Say
Biotech Market ChallengesBiotech investments and therefore biotech activity remains subdued due to macro pressures like weaker funding, FDA turmoil, NIH cuts, and tariff pressure.
Large Pharma DynamicsLarge pharma's shift to FSP models and declining sales amongst ICLR's top two customers are creating further pressure on '26 revenue growth.
Revenue Growth ChallengesThe prospect of seeing revenue growth in '26 is at risk, particularly given management now expects to see elevated cancellations persist throughout '25.
---
Ownership Overview
2.00% Insiders
28.17% Mutual Funds
2.03% Other Institutional Investors
66.58% Public Companies and
Individual Investors
ICLR FAQ
What was Icon plc’s price range in the past 12 months?
Icon plc lowest stock price was $133.28 and its highest was $347.72 in the past 12 months.
What is Icon plc’s market cap?
Icon plc’s market cap is $10.91B.
When is Icon plc’s upcoming earnings report date?
Icon plc’s upcoming earnings report date is Jul 23, 2025 which is in 75 days.
How were Icon plc’s earnings last quarter?
Icon plc released its earnings results on Apr 30, 2025. The company reported $3.19 earnings per share for the quarter, beating the consensus estimate of $3.105 by $0.085.
Is Icon plc overvalued?
According to Wall Street analysts Icon plc’s price is currently Undervalued.
Does Icon plc pay dividends?
Icon plc does not currently pay dividends.
What is Icon plc’s EPS estimate?
Icon plc’s EPS estimate is 3.2.
How many shares outstanding does Icon plc have?
Icon plc has 80,756,860 shares outstanding.
What happened to Icon plc’s price movement after its last earnings report?
Icon plc reported an EPS of $3.19 in its last earnings report, beating expectations of $3.105. Following the earnings report the stock price went down -4.114%.
Which hedge fund is a major shareholder of Icon plc?
Currently, no hedge funds are holding shares in ICLR
---
Icon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$193.07 (39.05% Upside)
$193.07 (39.05% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 232.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.13%
12-Months-Change
Fundamentals
Return on Equity
8.01%
Trailing 12-Months
Asset Growth
-1.91%
Trailing 12-Months
Company Description
Icon plc
ICON plc (ICLR) is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government organizations. The company operates within the life sciences sector, offering a comprehensive range of services that cover all stages of the clinical development process, from Phase I to Phase IV clinical trials. ICON's core services include clinical trial management, data analytics, regulatory consulting, and laboratory services, all designed to accelerate the development of new medical treatments and ensure regulatory compliance.
---
ICLR Company Deck
---
ICLR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted the company's achievements in operational efficiency and strategic expansions, particularly in AI and partnerships. However, these positive aspects were overshadowed by significant challenges, including revenue declines, elevated cancellations, and the impact of cancelled COVID trials on guidance. The overall sentiment reflects a cautious outlook due to ongoing market uncertainties.Read More>---
ICLR Stock 12 Month Forecast
Average Price Target
$193.07
▲(39.05% Upside)
Technical Analysis
Labcorp Holdings
―
Revvity
―
West Pharmaceutical Services
―
Penumbra
―
Medpace Holdings
―
---